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A 73-year-old Asian-American woman with end-stage renal disease
(ESRD) was evaluated for inordinately high urea distribution volumes
(V) calculated on the basis of single-compartment modeling of data
obtained from several hemodialyses (Table 1). The patient's renal
failure and hypertension had been managed with hemodialysis and
antihypertensive medications for 4 years. The cause of renal failure was
type-Il diabetes mellitus, which also had resulted in retinopathy and
poor vision; a brother and 3 sisters also had diabetes mellitus and
hypertension. Two years previously she had had increasing angina that
improved after coronary angioplasty. A chest radiograph showed
cardiomegaly and aortic calcification. One year previously she had had
persistent, non-healing ulcers on the plantar surface of the right foot
that resolved following percutaneous angioplasty of the right femoral
artery.
During the month preceding evaluation, her average blood pressure
was 161/83 mm Hg predialysis and 142/74 mm Hg postdialysis. At the
time of evaluation, her physical examination was remarkable for a
holosystolic murmur at the left sternal border that radiated to the axilla.
She had an easily palpable thrill and a high-pitched bruit at the
mid-portion of her left forearm loop Gore-Tex graft. Pedal pulses were
barely palpable; no peripheral edema was present.
Hemodialysis was prescribed for 3 hours thrice weekly with a
high-flux polysulfone dialyzer (1.8 square meter surface area). Dialysate
flow was set at 500 mI/mm and blood flow averaged 350 mI/mm; the
expected urea clearance was 245 mI/mm at these flow rates. Heparin
was limited to 750 units/hr infused intravenously during each hemodi-
alysis, but administered no later than 30 minutes before the end of
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treatment. Other medications included calcitriol, 0,5 ig, and erythro-
poietin, 3000 units given intravenously during each dialysis, oral
isosorbide dinitrate, pentoxifylline, lovastatin, diltiazem, enalapril,
enteric-coated aspirin, and sublingual nitroglycerin.
Her most recent hematocnt was 32%. Compliance with medications
and dialysis treatment was judged excellent as evidenced by no missed
treatments, adequate blood pressure control, an average serum phos-
phorus concentration of 4.7 mg/dl for the previous 6 months, and
normal serum albumin concentrations (Table 1).
Her vascular access, placed 4 years previously, was a left forearm
loop graft of woven polytetrafluoroethylene (Gore-Tex) interposed
end-to-side from the brachial artery to the basilic vein. The access
required declotting on one occasion 6 months after it was implanted, but
no apparent problems with the graft occurred subsequently. Venous
pressures averaged 186 mm Hg; arterial, —140 mm Hg. She was careful
to identify for each technician the appropriate limb of the graft for
placing the arterial inflow and venous outflow needles. Her poor vision
precluded her confirming the correct position of the needles, however.
She occasionally had muscle cramps and hypotension during dialysis
treatments that responded to reductions in ultrafiltration rate, to quinine
sulfate, or rarely to reducing dialyzer blood flow. During the preceding
year, her treatment time was lengthened from 2.5 to 3.0 hours per
dialysis because of frequent hypotension. Weight gain averaged 1.7 kg
between dialyses. Measured urine output was 500 mI/day and residual
urea clearance was 2 mI/mm. Urea kinetics were modeled at least
monthly. Table I illustrates results from the previous 7 months.
Discussion
DR. THOMAS A. DEPNER (Medical Director of Dialysis Ser-
vices, and Professor of Medicine, Division of Nephrology,
University of California at Davis, Sacramento, California):
Despite her extensive vascular disease and diabetes, this eld-
erly patient with ESRD has survived more than 4 years sus-
tained by hemodialysis. Now, however, she appears to be in
danger of underdialysis, as evidenced by the results of mathe-
matical modeling using the serum urea concentration obtained
during several hemodialyses. The increased use of mathemati-
cal modeling to assess adequacy of hemodialysis is partially
driven by a U.S. federal mandate (HCFA ESRD Network
Scope of Work, 1991—1993). As I will explain, modeling gives a
value for the ratio of dialyzer clearance to the patient's volume
of urea distribution (K,JV) [1]. The apparent urea distribution
volume (V) can be measured independently or can be calculated
from the ratio K,JIV and the expected dialyzer clearance (Kd)
obtained from dialysis specifications. When calculated in this
manner, the V of the patient under discussion, as shown in
Table 1, was larger on several occasions than her weight. This
obvious error stems either from overestimation of the expected
Kd or from a flaw in the mathematical modeling process itself.
Before examining the problem with V in this and other similar
patients in more detail, I will review some basics of urea
modeling in hemodialysis and show how V can be calculated in
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Table 1. The patient's monthly dialysis profile from a single-compartment variable-volume model of urea kinetics
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Month Jan Feb Mar Apr May June July
Predialysis: BUN, mg/dl 54 55 62 42 39 35 60
Weight, kg 49.5 50.7 50.6 51,0 51.8 50.8 50.8
Postdialysis: BUN, mg/dl 18 27 29 9 7 8 18
Weight, kg 47.8 47.8 48.6 49.0 49.0 48.9 49.0
V, % body wta 79% 123% 107% 50% 44% 48% 66%
Effective Kd, mI/mm 133 94 103 208 233 197 157
Kd, % expected 54% 38% 42% 84% 95% 90% 63%
PCRn, g/kg/day 0.86 0.73 0.84 1,08 0.85 0.88 1.00
Kit/V delivered 1.17 0.76 0.86 1.82 2.07 1.74 1.36
Reuse # 20 26 26 2 4 15 16
Serum albumin, g/dl &2 4.0 4.0 4.1 4.1 4.1 3)
a v is the urea distribution volume; K is the modeled (expected) dialyzer clearance for urea; PCRn is the normalized protein catabolic rate; and
K4•t/V is the fractional volume cleared of urea per dialysis.
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several ways [2]. A common misconception is that high values
for V indicate a flaw in the model [3—5]. This discussion will
show, in addition to other features of hemodialysis urea mod-
eling, that the flaw is usually in the dialysis, not in the model.
Prescribing hemodialysis
The physician has control over two elements of the dialysis
prescription, the dialyzer clearance (Kd) and the timing of
dialysis (duration [t] and schedule). When clearance is multi-
plied by duration, the result is the volume cleared (Kdt). If the
volume cleared is factored by the space of distribution of the
solute cleared (1'), the result is the fractional volume cleared
(Kdt/V), a dimensionless term familiar to most nephrologists.
When applied to urea, Kdt/V is widely accepted as a measure of
the amount or "dose" of dialysis given during a single treat-
ment [6]. The dose of dialysis is a "removed" dose, in contrast
to the "given" dose of a medication. It can either be a
prescribed dose based on expected Kd or an actually delivered
dose.
For urea, V is equivalent to body water volume, which is a
direct reflection of patient size. Factoring the volume cleared by
V is much like expressing the dose of a medication as a function
of body weight (for example, mg/kg), creating a universal
measure of dosage that is independent of patient size. If urea
clearance (Kd) is divided by V, the result is a fraction of the urea
volume that is cleared each minute or the fractional clearance
rate (Kd/V). In a true single-compartment system, this rate is
constant, known as the first-order rate constant or the elimina-
tion constant to students of pharmacokinetics. If both the
numerator and denominator of this fraction are multiplied by
the urea concentration (C), the fractional clearance rate
changes (conceptually) to fractional urea removal, an expres-
sion of rate that also is constant, and sometimes easier to
comprehend.
Unfortunately, we cannot calculate the total amount removed
by simply multiplying the rate (KdIV) by time on dialysis (t),
because the concentration of urea and the remaining amount of
urea change continuously during the treatment. The recirculat-
ing orientation of the dialyzer to the blood pool causes the urea
concentration to fall steadily. Dialyzed blood returns to the
pool, thus diluting the solute concentration and diminishing the
efficiency of the dialyzer. This process explains the inverse
geometric relationship between the amount of dialysis applied
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Fig. 1. The rate of solute removal diminishes as K't/V increases,
Percentages shown are the incremental removals associated with an
increase in Kt/V between the dotted lines.
and the amount of solute removed, and why the fraction K1t/V
can have a value greater than unity (Fig. 1). The efficiency of
dialysis depends on the rate of diffusion across the semiperme-
able dialysis membrane, a rate proportional to blood solute
concentration. The relationship between urea concentration
and urea removal can be expressed:
dt (1)
Kdk
C is urea concentration at any given instant; t is dialysis time; k
is the fractional clearance of urea; Kd is dialyzer urea clearance;
and V is the volume of urea distribution.
Integration of Equation 1 over the time span of a single
dialysis gives:
Kd tC = C0e -kt = C0e (2)
Kdt /c0\
__=ln) (3)
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In is the natural logarithm; C0 is urea concentration at the start
of dialysis.
Although KdtIV is not a measure of the amount of urea
removed during a dialysis treatment, it is nevertheless a valid
measure of the dialysis dose, that is, how much dialysis was
prescribed or delivered to the patient during a single treatment.
Equation 3 shows that KdtIV can be determined simply from
predialysis and postdialysis urea concentrations. When calcu-
lated this way, it becomes a measure of the delivered dose of
dialysis and can be compared with target values to judge
dialysis adequacy [6]. If the only intent is to measure dialysis
adequacy, one need not measure Kd, t, or V. This simplicity of
measurement is a fundamental property of delivered KdtIV that
endows its clinical application with both accuracy and practi-
cality.
To describe more accurately all the influences on urea
removal, we can expand Equation 3 to include the changes in
volume (LV) and urea generation (G) that occur during each
dialysis treatment (see Appendix A, Equations A-l and A-2).
Urea generation has a minor impact, but iV can increase Kdt/V
by as much as 30%. Both V and G add to the value of Kjt/V
determined from the simplified Equation 3. If Equation 3 is used
instead of Equation A-2 as the basis for dialysis adequacy, then
the true value for KdtIV will be higher; that is, the patient will
tend to receive more dialysis than prescribed and will be
relatively protected from underdialysis.
Origin of V
After KdtIV is determined from Equation 3 or its more
complex variants, either Kd or V can be resolved if an indepen-
dent value for the other (and t) is provided. An independent
value for Kd usually can be derived from the dialyzer's intrinsic
clearance and flow rates (see Appendix B, Equations B-l and
B-2). If this Kd is higher than the actual Kd achieved during the
dialysis (for example, because of inaccurate flow rates or
clotting during dialysis), V will be overestimated. The ratio
Kdt/V, however, remains accurate. If an independent and
accurate value for V is available, then Kd can be calculated from
Kdt/V and t. This value for Kd is the effective dialyzer clear-
ance. For example, if predialysis BUN is 50 mg/dl and postdi-
alysis is 20 mg/dl, then KdtI V is 0.92 (ln 50/20); this value will be
higher if significant weight loss has occurred during dialysis. If
the patient's true V is 30 liters and t is 180 minutes, the average
effective Kd for this dialysis is 153 mI/mm. Conversely, if the
expected 1d is 240 mI/mm, the apparent V is 47 liters. Even
when calculated using the more accurate complex methods, the
effective Kd in clinical practice is often lower than the expected
Kd, and the true V is lower than the calculated V. I will discuss
the reasons for these discrepancies in a moment.
Dialyzer clearance can vary from dialysis to dialysis or even
within a single dialysis, but V is relatively constant and there-
fore worth measuring independently. Techniques used to mea-
sure V have included dilution with markers of total body water
(for example, D20, tritium, urea, antipyrine) and whole-body
impedance measurements [7—10]. One technique that has prac-
tical value takes advantage of the hemodialysis itself; the
method is based on direct assessment of the amount of urea
removed from the patient, the inverse of indicator dilution
methods [11—141. It requires an accurate measurement of both
dialysate urea or urea nitrogen and the change in blood urea
Table 2. Causes of reduced dialyzer clearance (high 1')
Causes of real reduction in dialyzer clearance
Malfunction of the blood or dialysate pump
Low pre-pump pressure (blood pump)
Non-occlusion of rollers (blood pump)
Calibration error (e.g., wrong pump segment)
Faulty dialyzer
Clotting (inadequate anticoagulation)
Reuse of dialyzer
Channeling or incorrect blood/dialysate flow direction
Manufacturing defect
Access recirculation
Causes of apparent reduction in dialyzer clearance
Inflated dialyzer intrinsic clearance
Blood sampling or measurement error
(predialysis concentration too low,
postdialysis concentration too high)
Timing error (wall-clock syndrome) [35]
Modeling errors
concentration after equilibration (see Appendix C). With this
and other methods, the average values for V in patients with
end-stage renal disease are somewhat lower [15—18] than V
calculated from accepted anthropometric formulae [19, 201.
Causes of high V and reduced dialyzer clearance
If the dialyzer isn't clearing properly, V will be overesti-
mated because the expected value for Kd, which is used to
calculate V and which is obtained from both the dialyzer
specifications and flow rates (Appendix B), is inflated. The ratio
K/V determined from predialysis and postdialysis BUN is
presumed to be accurate, so any false elevation of Kd produces
a corresponding false elevation of V. Table 2 lists potential
causes of impaired dialyzer clearance.
A common source of error is the Kd reported in the manu-
facturer's specifications for the dialyzer; this value is often
obtained from measurements in vitro using water or saline [21].
A manufacturer's access to patients and blood is usually
limited, so pure aqueous or saline solutions generally are used
to measure the dialyzer's intrinsic clearance from the inverse of
the equations in Appendix B. Clearance from pure aqueous or
crystalloid solutions is always higher than that from blood
because of the blood's reduced water content, higher viscosity,
and delayed diffusion from red cells. For urea, water content is
the only significant influence; the effective water content of
blood is approximately 90% and varies slightly with hematocrit
[22, 23]. For this reason, we have recommended a 10% reduc-
tion in expected urea clearance from that calculated using
manufacturer's specifications [24]. A better correction is ob-
tained by measuring instantaneous urea clearances in vivo in a
large number of patients for each dialyzer in use [21]. This
approach allows an assessment of variance as well as the mean
value for intrinsic clearance using each dialysis clinic's own
equipment.
All currently used blood roller pumps register flow as a
function of the pump speed in revolutions per minute (RPM).
These pumps propel the blood forward against a high-pressure
resistance created by the dialyzer, the tubing, and the venous
access needle. Resistance to flow on the inflow side creates a
low-pressure zone in front of the roller. As each roller com-
pletes its stroke and lifts off the roller track, pressure in the
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segment of tubing between the rollers suddenly rises by 200 to
500 mm Hg. This increased pressure creates a short reversal of
flow as the segment expands. Depending on the tubing's resil-
ience and hysteresis effects, this reversal of flow can be a
significant fraction of total blood flow. The RPM meter does not
adjust for this pressure effect [25]. When the pre-pump pressure
falls to —400 mm Hg, and before the tubing shows visible signs
of collapse, flow can be reduced to less than one-half that
indicated by the RPM meter [26]. It is therefore important that
one monitor the pre-pump pressure and prevent the negative
pressure there from falling below —200 mm Hg. Similarly,
failure of roller occlusion or inaccurate pump calibration can
reduce flow below that indicated by the RPM meter and cause
a reduction in dialyzer clearance.
The dialyzer can lose volume and surface area during hemo-
dialysis from clotting if the dose of heparin or other anticoagu-
lant is insufficient [27, 28]. This phenomenon can cause a
progressive decline in clearance during the treatment. Clots that
form during dialysis can be flushed out between treatments in
multiply used dialyzers, but failure to remove clots or other
debris during reprocessing reduces the clearance for the next
dialysis [29, 30]. Reprocessing procedures should include a
check of fiber bundle volume or clearance to guard against this
cause of clearance loss. The method of measuring residual
volume or clearance itself should itself be checked periodically
using an independent, usually manual, technique [31]. Gotch
and others have shown that clearance falls by less than 10% if
the dialyzer is discarded when the blood-side volume falls
below 80% of the original volume [30, 32].
Incorrect connections that route blood and dialysate flow in
the same direction instead of the more efficient countercurrent
direction can reduce clearance [22, 33]. Defects in the dialyzer
due to manufacturing variance or errors have been associated
with non-uniform flow and with channeling of blood and dialy-
sate flow, and these defects also reduce clearance [34]. Finally,
dialysis may be temporarily halted or blood flow decreased for
a variety of reasons during the treatment. Most patients and
staff anticipate ending the dialysis session at a predetermined
time. The "wall-clock syndrome" is an error in timing that
results from failure to subtract the "down time" from the
patient's dialysis duration [35]. The inflated duration of dialysis
causes an apparent decrease in KjV (Equation 3), most often
reported as a decrease in effective clearance.
Recirculation in the vacular access
One of the most common causes of a decrease in effective
clearance is recirculation in the access device [36—38]. Access
recirculation is defined as the immediate return of venous
(dialyzed) blood to the dialyzer. Access recirculation does not
impair dialyzer clearance directly, but reduces the efficiency of
dialysis by limiting afferent inflow of blood from the patient to
the dialyzer. Recirculated venous blood from the dialyzer
dilutes the incoming systemic blood, lowering the concentration
gradient across the dialyzer membrane. Recognizing access
recirculation is essential because this process forecasts failure
of the device due to clotting [25, 38, 39, 47]. A number of
factors, including proximal and distal stenoses in an arterio-
venous shunt, close approximation of needles, and reversal of
the inflow and outflow needles, can predispose to recirculation
(Table 3). Pumping blood through the dialyzer at high rates can
Table 3. Causes of A-V graft or fistula recirculation
Fixed stenosis, arterial or venous
Reduced blood flow to the graft extremity
Peripheral vascular disease
Reduced cardiac output
Peripheral vasoconstriction
Malposition of the access needles
Close proximity
On same side of a mid-graft stenosis
Reversal of dialyzer arterial and venous lines
Increased dialyzer blood flow
Table 4. Access recirculation: measuring techniques
Solute concentration methods [2, 45, 84]
Urea modeling [2, 35]
Dilution techniques
Dye or indicator
Thermal dilution [46, 85]
Hemoglobin dilution with saline [86]
Bedside occlusion/pressure measurements [49]
cause or accentuate recirculation [36, 40]. If the needles are
widely separated in an arteriovenous (A-V) fistula, recirculation
indicates reversal of flow between them. In extreme circum-
stances, all the dialyzed blood returns to the dialyzer, effec-
tively removing the patient from the dialyzer circuit and elimi-
nating the benefits of dialysis.
Measurement of recirculation has undergone careful scrutiny
within the past 3 years because the previously held "gold
standard" that compared the BUN in venous blood from the
opposite arm with arterial blood entering the dialyzer has been
discredited [41—44]. Patients can have a significant urea gradient
between the two arms despite the absence of access recircula-
tion. The gradient between the two arms is accentuated at lower
temperatures and in patients who have poor circulation in
superficial veins. Table 4 lists a variety of methods that have
been advocated for detecting and quantifying recirculation. The
most popular method requires nearly simultaneous measure-
ments of solute concentrations in the dialyzer inlet, the dialyzer
outlet, and the afferent limb of the access device (Appendix D).
Measurements of dialyzer clearance fail to detect recirculation
because the dialyzer is not the cause or the site of the distur-
bance. Recirculation from any of the causes listed in Table 3
can be intermittent. The wide variance reported for repeated
measures of recirculation in the same patient supports this
concept [45].
Urea modeling to detect local access recirculation
Detection of recirculation as a sign of impending access graft
failure is one of the most useful applications of urea modeling.
Recirculation in the vascular access during hemodialysis is
suggested when V is inordinately high or effective Kd is lower
than expected. The magnitude of recirculation can be expressed
quantitatively from the difference between expected and effec-
tive dialyzer clearances [21:
Kd — KdeFr =
Kd— Kde + Kd Kde/Qb (4)
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F is the fraction of dialyzer blood flow consisting of recircu-
lated blood; Kd is the expected dialyzer clearance; Kde is the
effective dialyzer clearance; and Qb is the dialyzer blood flow
rate. Any solute can be measured to quantitate recirculation,
but urea is the most sensitive and therefore the most frequently
measured. The negative impact of recirculation on clearance is
greater for solutes that are easily dialyzed such as urea. The
clearance of larger, less diffusible solutes depends more on
membrane permeability and surface area than on blood flow.
Access pressure monitoring
Vascular access has been called the "Achilles heel" of
hemodialysis [39]. Without the access device, maintenance
hemodialysis would not be possible, but the device also limits
the potential of hemodialysis by limiting dialyzer blood flow. In
many cases, access recirculation masks the reduction of blood
flow that otherwise would be revealed by pressure-monitoring
devices at the bedside. For example, if recirculation were not
possible, stenosis at the venous (proximal) end of the vascular
access would always cause high pressure in the venous return
line. Recirculation relieves the potential pressure build-up and
may completely eliminate any pressure increase. This fact
forms the basis for the occlusion method for detecting recircu-
lation (Table 4) and might explain the failure of pressure
monitoring to reliably detect access stenosis in some patients
[46-49]. Ifa stenosis exists in the mid-portion of the vascular
access and the needles are placed on either side of it, the
potential for recirculation is reduced or eliminated. Except for
the predisposition to thrombosis, mid-access stenosis benefits
the patient because it restricts flow, reducing the risk of
high-output cardiac failure between dialyses, but does not
restrict flow during dialysis. Like stenosis at the venous end,
however, recirculation relieves the vacuum effect of stenosis at
the arterial end of the vascular access and diminishes the
reliability of arterial pressure monitoring as an indicator of
stenosis at that location. Vascular access continues to be a
roadblock in the quest for improved dialysis efficiency. Consid-
ering these masking effects of recirculation, the possibility of
access stenosis should be considered in any patient whose
dialyzer is functioning suboptimally regardless of pressure
measurements in the blood lines.
Another cause of an apparent reduction in clearance is an
error in the modeling process itself, that is, choice of an
inappropriate model (Table 2). Table 5 catalogues several of the
currently recognized modeling errors. Ignoring significant vol-
ume changes or urea generation during dialysis causes an error
in the opposite direction, that is, one will underestimate dia-
lyzer clearance. Much concern has been raised in recent years
about delayed urea removal due to multi-compartment phenom-
ena causing solute disequilibrium, especially during high-flux
dialysis [50].
Solute disequilibrium
Solute disequilibrium can be defined as a concentration
difference or gradient among compartments for a dissolved
compound. Access recirculation is a form of solute disequilib-
rium localized to the vascular access device. If significant
recirculation occurs, the concentration of solute entering the
dialyzer is lower than the concentration in the patient. Solute
disequilibrium also can occur within the patient and, like access
recirculation, these gradients also reduce the effectiveness of
dialysis [42, 43, 51].
Evidence for disequilibrium within the patient is found in the
rapid fall in blood urea concentration shortly after hemodialysis
is begun and in the rebound of blood urea concentration after
dialysis is stopped (Fig. 2) [50]. Urea concentrations in the
blood compartment are not well predicted by the simple single-
compartment model but can be adequately described if a
two-compartment model is applied (Fig. 2) [2, 50]. The latter
model of urea kinetics includes a term for resistance to diffusion
between two body compartments; this resistance allows urea
concentrations in blood to fall more rapidly than urea concen-
trations elsewhere in the body during hemodialysis treatments.
The standard two-compartment model, however, assumes that
the blood pool itself is uniformly mixed during hemodialysis.
In the past, disequilibrium for urea and other compounds was
thought to develop primarily because of resistance to diffusion
across cell membranes (membrane-dependent disequilibrium)
[7, 52—54]. More recently, differences in blood flow among
tissue capillary beds have been shown to cause concentration
gradients within the blood compartment itself [41, 42]. This
blood-flow-dependent disequilibrium has been well described
for drugs and for other intravenously injected markers but had
Table 5. Modeling errors
Failure to include significant variables in the model
Volume change during hemodialysis
Urea generation
Native kidney clearance
Failure to account for solution disequilibrium from:
Cardiopulmonary recirculation
Slow peripheral circulation
Increased membrane resistance to solute diffusion
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Fig. 2. Measured BUN values during a single (150 minute) hemodial-
ysis (•) compared with predictions by a single-compartment, variable-
volume model (dotted line) and a two-compartment, variable-volume
model (solid line).
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Hg. 3. Postdialysis sampling time is critical. A is the immediate
postdialysis sample. B is an immediate postdialysis sample taken from
the afferent limb of the access device (access recirculation eliminated)
using the technique in Appendix D. C is delayed 2 minutes postdialysis,
eliminating the effects of cardiopulmonary recirculation. D is delayed
one hour, when urea equilibration throughout the body is essentially
complete.
not been appreciated during hemodialysis [55—57]. A specific
example of this type of disequilibrium is found in the recently
described cardiopulmonary recirculation that occurs during
hemodialysis in patients with peripheral A-V shunts [51]. The
relatively rapid flow of dialyzed blood through the heart and
lungs and back to the dialyzer reduces the solute concentration
in this circuit loop to a level lower than that in the remainder of
the circulation. This and other rapidly flowing circuits diminish
the efficiency of the dialysis process by diluting blood entering
the dialyzer with blood that is already dialyzed, effectively
limiting blood flow from the remainder of the body to the
dialyzer. Schneditz et al recently described a mathematical
model of blood-flow-limited disequilibrium based on differential
blood flow through other capillary beds in addition to the
cardiopulmonary circuit [58]. This model differs from standard
two-compartment models used in the past because it assumes
infinite urea permeability (no resistance to urea diffusion) within
the entire urea space, including the cell membrane. These and
other investigators [41—44] have demonstrated the potential
significance of blood flow as a determinant of solute disequilib-
rium. The relative importance of membrane-dependent and
flow-dependent disequilibrium remains to be clarified.
Although solute disequilibrium within the patient is a poten-
tial cause of underdialysis, it will not produce an inordinately
high postdialysis BUN if the postdialysis blood sample is drawn
before the BUN rebounds. The postdialysis BUN is a more
sensitive determinant of K1t/V than the predialysis BUN, and
timing of sampling is critical, as shown in Figure 3. One should
avoid sampling at point A, when recirculation within the access
device can markedly distort the results of urea modeling. Most
dialysis centers currently sample at point B and use one of the
techniques listed in Appendix D. Sampling approximately 2
minutes following dialysis at point C avoids both access recir-
culation and cardiopulmonary recirculation [59]. The relatively
steep slope of the rebound curve at this point necessitates
KW
Fig. 4. The error in V from inappropriate use of single-compartment
modeling depends on the intercompartment mass-transfer coefficient(KC) and K1t/V (x-axis). The error in V shown on the right y-axis
represents the ratio of urea volume determined by a single-compart-
ment, variable-volume model (V,) to the volume determined by a
two-compartment, variable-volume model (V2).
accurate timing and likely decreases the precision of measure-
ment. Unfortunately, the BUN in a small but significant number
of patients rebounds slowly and does not reach equilibrium until
30 to 60 minutes after stopping dialysis. We have no means of
identifying these patients at the present time, so to reach point
D with certainty, all patients would have to wait one hour
before sampling.
Each of the three causes of disequilibrium listed in Table S
reduces the postdialysis BUN to levels lower than equilibrated
values. By itself, this effect tends to decrease, rather than
increase, apparent V and gives an inordinately high value for
modeled dialyzer clearance. Offsetting this effect, however, is
an overestimation of the amount of urea removed during
hemodialysis [2, 14]. The net effect is usually zero; that is, V
determined by one-compartment, variable-volume modeling is
usually an accurate measure of V, provided Kd and t are
accurate [2, 18]. Figure 4 shows that the single-compartment,
variable-volume model of urea kinetics has a greater tendency
to underestimate rather than overestimate V than does the more
accurate variable-volume, two-pool model. The curves in Fig-
ure 4 are similar to those published by Gotch, who also used
theoretical arguments to predict the single-compartment error
in V [35]. Paradoxically, at higher levels of K1t/V within the
clinically achievable range, when disequilibrium should be
greater, V is even more accurate. Recent data obtained from
our own patients confirmed the accuracy of V and Kdt/V
measured with the single-compartment variable-volume model
[18].
Definitions of clearance
A source of much confusion and misunderstanding about
urea modeling can be traced to the definition of clearance. Table
6 classifies hemodialysis clearance and how each type of
clearance is measured. Although I've already mentioned the
distinction between expected clearance and effective clearance,
I think it bears repeating. Expected clearance is derived from
the dialyzer's intrinsic clearance and flow rates (Appendix B).
Effective clearance is a measure of dialysis outcome and is
derived from predialysis and immediate postdialysis BUN
36
32 D
28
24
..
20 A
16
—40 —20 0 20 40 60
Time, minutes postdialysis
Undefined
>, disequilibrium
NardiopuImonary
.— recirculation
Access
recirculation
E
0
2000
800
400
200
1.40
1.20
1.00 >
080• >
0.60
0.40
0.5 1.0 1.5 2.0
1528 Nephrology Forum: Urea modeling in dialysis
Table 6. Hemodialysis clearance
Type Measurement required
Dialyzer clearance
Instantaneous clearance
Blood side Simultaneous predialyzer and
postdialyzer blood solute
concentrations and blood flow
Dialysate side Simultaneous predialyzer blood solute
concentration, dialysate solute
concentration, and dialysate flow
Expected clearance Dialyzer intrinsic clearance, average
blood flow, and average dialysate
flow
Effective clearance Predialysis and postdialysis blood
solute concentrations, volume of
solute distribution
Intrinsic clearance Instantaneous clearance, blood flow,
and dialysate flow
Patient clearance Predialysis solute concentration,
postdialysis equilibrated solute
concentration, and true volume of
solute distribution
(point B in Fig. 3) using Equation 3 or Equations A-i and A-2.
Both expected and effective clearances are measures of dialyzer
clearance. Differences between them usually can be attributed
to the problems listed in Table 2. If none of the conditions listed
in Table 2 exists, then expected clearance should match effec-
tive clearance, and both should match the instantaneous clear-
ance derived from simultaneous measurements of solute con-
centration across the dialyzer either on the blood or on the
dialysate side.
A fifth measure of clearance, the patient clearance, can differ
significantly from the others. Sometimes called whole-body
clearance, patient clearance represents the net effect of dialysis
in the patient. Achieving an adequate or optimal patient clear-
ance is the ultimate goal of hemodialysis. Since the patient can
no longer be considered as having a well-mixed pool of solute,
dialyzers that perform well even in the absence of local access
recirculation do not necessarily dialyze the patient well. The
ultimate result in the patient depends on patient-specific param-
eters that are just beginning to be understood.
The patient is, in this limited respect, like a hollow-fiber
kidney, that is, a series of parallel capillaries that equilibrate
with interstitial fluid. Solute moves from the tissues into the
blood in the "patient kidney" and from blood into the dialysate
passing through the extracorporeal "kidney." This two-dia-
lyzer model of dialysis has been used to explain bulk removal of
solute from the patient during hemodialysis. Detailed examina-
tion of solute kinetics during hemodialysis not surprisingly has
shown that the patient is more complex than the extracorporeal
kidney. The patient is like a series of dialyzers connected in
parallel with differing blood and "dialysate" flows (Fig. 5) [42,
57, 58]. Dialysis produces changes in solute concentration in
each compartment at varying rates and eventually leads to
significant differences in concentration among the compart-
ments. Unlike a capillary bed with low blood flow, a capillary
bed of similar size with high blood flow depletes its solute
content more quickly and becomes a site for recirculation, thus
becoming a source of reduced dialysis efficiency.
Capillary blood flow is a major determinant of tissue solute
clearance, but bulk removal of solute also depends on tissue
volume (Fig. 5). For example, clearance of solute from the heart
and lungs is potentially high because of the high blood flow
there, but these tissues provide relatively little solute for
removal because of their small mass. This relationship is like
dialysis with high blood flow but with little dialysate flow. In
other capillary beds, like the skin in a cold environment, blood
flow can be low in comparison to tissue volume. Increasing flow
through the cardiopulmonary circuit may do little to improve
solute removal from the patient, but even small increases in
skin or muscle flow can send larger amounts of solute to the
dialyzer [41, 51].
Complicating this picture is the potential for resistance to
diffusion across capillary and cell membranes. The complex
relationship of clearance to blood flow and membrane resis-
tance is also modulated by solute-specific variables such as
molecular weight and macromolecular binding. All these influ-
ences create or accentuate solute disequilibrium within the
patient. Solute disequilibrium accounts for the difference be-
tween patient clearance and dialyzer clearance. To the extent
that disequilibrium within the patient increases, patient clear-
ance falls below dialyzer clearance.
Patient clearance can be measured by quantitating all solute
(for example, urea) removed during a dialysis treatment or by
applying a single-compartment model to predialysis and equil-
ibrated postdialysis solute concentrations [13, 60, 61]. A value
for patient clearance would seem to be the best measure of
dialysis effectiveness because patient clearance, not dialyzer
clearance, is the treatment goal. But current standards against
which the adequacy of dialysis is measured, such as ideal values
for Kt/V provided by the U.S. National Cooperative Dialysis
Study (NCDS), have used dialyzer clearance to quantitate the
dialysis effect [6, 33, 62]. We have no standards with which to
compare patient clearance. If patient clearance is used instead
of Kd in the expression of delivered dialysis dosage, KtIV is
always lower. Additional population outcome studies will be
required to allow the use of patient clearance as an acceptable
measure of dialysis adequacy.
Protecting the patient
For all the reasons I have mentioned, patients often receive
less dialysis than the physician prescribes [4, 63—66]. The most
common causes of differences between prescribed and deliv-
ered treatment are reductions in clearance (Table 2). Each of
the items listed in this table increases the risk of inadequate
dialysis. Giving less than optimal treatment is a form of "short-
changing" the patient that reduces labor and cost. Unfortu-
nately, advocates of more frequent or longer dialysis are
sometimes hard to find in the dialysis center. Shortened dialysis
is all too often sanctioned or requested by patients themselves.
Because the lobbyists for less frequent or shorter dialysis
outnumber those advocating more frequent or longer dialysis,
patients are in danger of undertreatment unless the dialysis
center has a method for objectively and correctly evaluating the
adequacy of the dialysis prescription. Although urea is only a
marker for more toxic compounds, I and many other nephrol-
ogists believe that objective quantitation of dialysis through
urea modeling, applying the standards set forth by the NCDS,
protects patients from underdialysis as well as from people,
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Fig. 5. Proposed model of the patient as a composite of capillary beds
arranged with parallel blood-flow circuits. In comparison with more
proximal capillary beds with high flow/tissue fluid volume, the more
distal circuits have reduced flow and higher solute concentrations,
depicted here as a higher density of dots.
including patients themselves, who would like to reduce the
dosage [33, 67].
Additional studies in the patient presented
The effective dialyzer clearances in the patient presented
today (Table 1) were derived from the true urea distribution
volume (V) using the dialysate method described in Appendix
C. During two separate dialyses, V measured 20.3 and 20.8
liters (42% of body weight). Initial measurements using the
low-flow technique (Appendix D) showed no evidence of recir-
culation in the access device. Blood and dialysate pump flow
rates were tested and found accurate. Prepump pressure was
limited to —200 mm Hg during all dialyses. Because of the low
heparin dosage and her multiply reused dialyzers, instanta-
neous urea clearances were measured several times on both the
blood and dialysate sides during multiple treatments. Blood-
side clearances were nearly identical to clearances predicted
from the dialyzer intrinsic clearance and flow rates according to
Equations B-I and B-2. Dialysate clearances matched blood-
side clearances, thereby ruling out an erythrocyte diffusion
defect [23]. Despite the excellent dialyzer performance, during
one test dialysis the effective urea clearance measured from
predialysis and postdialysis BUN was almost one-half of the
measured clearance, and the urea distribution volume was again
larger than the patient's weight. The marked difference between
measured and effective clearance suggested that an inappropri-
ate model of urea kinetics had been applied to this unusual
patient whose modeling discrepancies might have been caused
by solute disequilibrium within the patient.
Among the factors that predisposed to solute disequilibrium
were her advanced age, her extensive cardiovascular disease,
and the persistent intolerance of fluid removal that necessitated
extension of her dialysis time [68, 69]. Her relatively small size
and disproportionately low V in the setting of high-flux dialysis
also raised the likelihood of solute disequilibrium within the
patient [2, 70, 71]. Because of the theoretical limitations of
solute disequilibrium as a cause of increased V, however, we
focused on access recirculation as the likely problem.
Several factors pointed to a possible defect in her A-V shunt.
She had an easily audible, high-pitched bruit at the mid-portion
of the graft, and because of her poor vision she could not
confirm placement of the needles. Using the low-flow tech-
nique, over 30% recirculation in the access device was subse-
quently found during two hemodialyses. No changes in either
arterial or venous pressures were observed at 350 mllmin blood
flow; such alterations would have indicated possible access
stenosis. Subsequent angiography showed significant stenoses
at three locations in her forearm graft.
This case extends our understanding of recirculation as an
intermittent process. I can only speculate that the cause of the
intermittent nature of her access recirculation was placement of
the needles. Other causes such as intermittent reduction of flow
to the extremity (Table 3) cannot be excluded. Following
angioplastic correction of the stenoses, her urea modeling
studies returned more reasonable values for V (45% and 47% of
body weight) and no recirculation could be detected. Moreover,
the patient herself subsequently reported feeling better and
stronger after her access was repaired.
Conclusions
In addition to assessing adequacy of dialysis, mathematical
modeling of predialysis and postdialysis urea concentrations—
even with the less-accurate single-compartment model—is a
valid screen for correctable disorders that diminish the effec-
tiveness of hemodialysis. This function of modeling has clinical
value because it focuses the caregivers' attention on patients,
equipment, or both that warrant further investigation. To assure
the validity of data from urea modeling, one should draw the
postdialysis BUN either immediately at the end of treatment,
taking steps to avoid access recirculation errors, or within 2
minutes of completion of dialysis. Urea modeling can detect
vascular access recirculation, an adverse development that not
only decreases the effect of hemodialysis but often heralds
stenosis in the access device. Recirculation can prevent venous
pressures from rising and pre-pump pressures from falling when
stenoses develop, so pressure monitoring is an unreliable pre-
dictor of graft failure from stenosis. Studies in patients such as
the woman presented today lead us to conclude that high values
A-V fistula
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of modeled V, if modeling is done correctly, are usually if not
always the result of underdialysis. The focus of attention in
such cases should be directed to the patient's dialysis procedure
including the dialyzer itself, the blood pump, and the access
device. Solute disequilibrium within the patient is rarely a cause
of a reduction in clearance as it is currently measured. If
recirculation in the access device is not detected using the
low-flow or stop-flow technique, and measured dialyzer clear-
ances are adequate, consideration should be given to the
possibility of intermittent access recirculation and to investigat-
ing the access device.
Questions and answers
DR. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Could
you summarize the evidence correlating biochemical measure-
ments of adequacy of dialysis, for example, Kt/V, and func-
tional measurements, such as peripheral and central nervous
system function?
DR. DEPNER: Numerous studies have been conducted over
the past 30 years in attempts to give us a better index of
adequacy. These ranged from basic measurements of blood
concentrations of a variety of solutes, to measurements of
higher organ functions such as peripheral nerve conduction and
latency, to measurements of EEG power spectrum analysis and
evoked potentials [72—75]. The limited success of early attempts
to resolve the question of adequacy in a more definitive way
created the need for more expensive population studies con-
ducted later by the NCDS. The popular theory that middle
molecules accounted for the toxic effects of uremia was largely
discounted by the NCDS in the late 1970s. The additional
finding that the BUN, when examined by itself, can be mislead-
ing paved the way for the application of KtIV, a measure of
dialyzer effectiveness that reflects both the urea level and the
patient's urea generation rate. KtIV has not been correlated
with specific biochemical or toxic effects but rather with patient
outcomes considered by many to be a more sensitive index of
uremia. The correlation of better outcome with higher Kt/V
was an empiric conclusion, not the primary objective of the
NCDS, but the results were striking. Perhaps the failure to
correlate objective measurements such as a toxin level or an
organ dysfunction with the severity of uremia or its converse,
the adequacy of dialysis, is related to the subtlety of the uremic
syndrome itself. This syndrome might be the result of a wide
variety of toxic phenomena that act in concert, each of which is
below the limits of detection. I'm afraid that we have not been
able to develop the more definitive biochemical or functional
tests you suggest. This has been disappointing but we hope that
we will in the future.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): We've become
increasingly sophisticated in being able to measure the therapy
that we're prescribing for dialysis patients, yet some clinicians
argue that the U.S. mortality rate exceeds that in Europe. How
do you account for this discrepancy?
DR. DEPNER: The difference between mortality rates in this
country versus Europe has been attributed to several factors.
The European data probably are not as accurate as data from
the U.S. Renal Data System because the information is col-
lected on a volunteer basis. The centers with poor outcomes
might not report as readily as those with good outcomes.
Second, the selection of patients is different. For a variety of
reasons, partly the ease of implementation and success of
dialysis, we accept for dialysis more and more patients with
short life expectancies in this country; this practice is not
common in Europe. Studies by Collins in Minnesota have
demonstrated the contribution of comorbid conditions to high
mortality in the U.S. [76]. Third, because the NCDS findings
focused attention on urea and away from middle molecules,
some nephrologists in this country might have been misled into
thinking that shortening dialysis time was all right as long as the
BUN was unchanged. The popular trend to shorten dialysis
time, partially driven by patient pressure and economic factors,
has reduced dialysis time to an average of 3 hours in the U.S.
compared with Europe, where treatment time remains at 4 to 5
hours. Although clearances were increased appropriately in
some U.S. centers, in others shortening occurred without an
increase in clearance, and in many no attempt was made to
measure dialysis adequacy. The value of monitoring Kt/V has
been confirmed by several investigators who compared out-
comes in centers where Kt/V is low or not measured, with
outcomes in centers where Kt/V is maintained at levels above
1.0/dialysis [63, 66, 77, 781. The latter centers have outcomes
that compare favorably with the European centers. Judging
from my own experience, patient selection appears to be a
major factor. The adequacy of dialysis, however, may loom
larger as a cause of morbidity and mortality in centers that do
not monitor Kt/V or another index of adequacy.
DR. MADIAS: Is there any level of Kt/V that will direct you to
advise a reduction in dialysis time?
DR. DEPNER: In other words, can you excessively dialyze the
patient? There is no evidence at present that one can exces-
sively dialyze a patient lithe dialysis is performed properly. In
the past, problems arose with acetate intolerance, bio-incom-
patible membranes, and erratic ultrafiltration that fostered a
sense that hemodialysis causes both beneficial and detrimental
effects. Even with the best equipment and techniques today,
patients continue to feel weak and fatigued following the
treatment, but they apparently have no long-lasting effects. In
his original domain map depicting K t/V with mid-week BUN
and nPCR, Gotch showed a region of questionably excessive
dialysis mostly based on economic considerations [6]. Dialysis
caregivers should be aware that when improperly administered,
hemodialysis can cause harmful effects (for example, aluminum
and endotoxin exposure, amyloid formation), but when current
standards are maintained, there is no evidence to support the
concept of excessive dialysis. Evidence to the contrary has
appeared that increasing Kt/V to 1.4/dialysis or above, thrice
weekly, is associated with a decrease in morbidity and with
longer life span [67, 79, 80].
DR. JAMES STROM (Chief of Nephrology, St. Elizabeth's
Hospital, Brighton, Massachusetts): When recirculation is
present, why does dialyzer urea clearance, measured by dialy-
sate collection, correlate better with published standard dia-
lyzer clearance than with modeled urea clearance?
Dn. DEPNER: The dialysate method for measuring instanta-
neous clearance works just like the blood side method. It simply
measures what the dialyzer is doing, based on what is going into
the dialyzer and what is coming out. Dialyzer clearance is not
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affected by recirculation because the input arterial concentra-
tion is measured at the arterial sampling port, downstream from
the site where recirculation occurs. Even when effective clear-
ance is markedly reduced by recirculation, we would expect
measurements of dialyzer clearance, either on the blood or
dialysate side, to equal the expected (published) clearance,
based on the dialyzer's intrinsic clearance and flow rates.
DR. STROM: What do you think about the trend toward using
urea reduction ratios to Kt/V as an indicator of dialysis ade-
quacy?
DR. DEPNER: The urea reduction ratio (URR), defined as the
change in BUN during dialysis divided by the predialysis BUN,
is a simplified method of measuring dialysis adequacy. It is less
accurate than more complex methods but is better than no
measurement at all. It fails to consider volume changes (LV),
urea generation, and residual native-kidney function during
dialysis. Of these, iW is the most important; if ignored it can
cause an error as high as 30% in the estimate of dialysis
delivered. Urea generation is less important, and residual
clearance can almost always be ignored when accessing either
KtIV or URR. The error is always in favor of the patient.
Physicians using the URR without adjustment for V or urea
generation will conclude that more dialysis is required to
achieve the target KtIV than is actually necessary. The URR
correlates in a curvilinear fashion with Kt/V. A nomogram is
available for converting URR to Kt/V that takes into consider-
ation both LW and urea generation [81]. I prefer formal urea
modeling because it is more flexible and accurate. The equa-
tions are complex but require only a few more milliseconds to
solve by computer.
DR. KLEMENS MEYER (Division of Nephrology, New En-
gland Medical Center): You made a strong case for using
single-compartment modeling. Are there circumstances in clin-
ical practice in which you think double-compartment modeling
is needed?
DR. DEPNER: Probably the most significant error from the use
of single-compartment modeling is in the calculation of the
protein catabolic rate (PCR). The PCR will be overestimated by
the single-compartment model because the postdialysis BUN is
lower than the equilibrated postdialysis BUN, and the single-
compartment model assumes no rebound. The slope of the line
connecting the postdialysis BUN with the next predialysis
BUN, a correlate to PCR, is higher than reality and will deviate
more from true PCR in patients with more rebound. Clinically,
this is rarely a problem, because the variance in PCR is so large
anyway (CV - 15%). If one wants to be precise about mea-
surements of PCR, for instance in a clinical research setting,
then the two-compartment model would be helpful. Concerns
about overestimating V are unfounded, as today's case discus-
sion illustrates. The risk of underestimating V is more real, but
as Kt/V increases, the accuracy of V, as determined by
single-compartment modeling, actually improves (Fig. 4). If the
goal is to measure patient clearance and patient Kt/V, then
either a two-compartment model or a dialysate method is
required.
In years to come, we should focus more on the patient's
clearance and patient Kt/V than on our current definition of
K•t/V as dialyzer clearance multiplied by dialysis duration
divided by urea volume. Patient clearance is a measure of the
patient's response to dialysis, rather than the amount of dialysis
delivered to the patient. Because the standard for Kt/V was
established by the NCD study wherein single-compartment
modeling was used, at present single-compartment methods
continue to be appropriately applied in most dialysis centers.
Because the ultimate goal of urea modeling is measurement of
patient response to dialysis, I believe that in the near future we
will see more application of dialysate methods.
DR. MEYER: We have started to use the technique you
describe to measure access recirculation. Most of our patients
have 0% recirculation. What has your experience been?
DR. DEPNER: Our experience has been similar to yours. In
most of our patients, like the one presented today, who have
recirculation measured because they had high modeled Vs, the
recirculation percentage using the low-flow technique has been
zero. As a result of our experience with this patient, we are
more concerned about remeasuring it, looking for intermittent
recirculation perhaps related to needle positioning in the fistula.
If the arterial needle is placed upstream and the venous needle
is placed downstream of a stenosis in the access device, no
recirculation will occur. If both are placed on either side of the
stenosis, recirculation is likely. If fistula flow diminishes during
dialysis, recirculation can begin to appear. The cause of high V
is not always recirculation, however. We have found problems
with our reuse equipment, blood pumps, and dialysate pumps
that caused true decreases in dialyzer clearance.
DR. HARRINGTON: What is your best estimate of the percent-
age of patients whom you believe are underdialyzed in the
United States? From a public policy standpoint, what would
you do to assure that the government, who pays for dialysis,
actually obtains adequate dialysis? Should everybody have a
K•t/V weekly? Monthly? What would you demand if you were
the Dialysis Czar?
Da. DEPNER: The percentage of patients whose delivered
Kt/V is less than 1.0/dialysis has been examined by several
investigators who report incidences from 0% to 50% in different
centers [63, 64, 66, 78]. These are rough figures based mostly on
pre/post-dialysis BUN without consideration for volume loss,
urea generation, or residual clearance. Part of your question has
already been answered by "czar"-like people. The Health Care
Finance Administration (HCFA) in 1990 included in its Scope
or Work mandate to the ESRD Networks that assessment of
dialysis adequacy must be a part of their case reviews for
1991-4993. As a result, many centers were compelled to begin
regular measurements of Kt/V or URR. Ideally, Kt/V should be
measured on line with each dialysis, so that each individual
treatment would be rendered adequate. Methods for deploying
such a plan exist but are prohibitively expensive. In our own
center, we examine urea kinetics once a month, using a formal
computerized method. Present HCFA guidelines state that
dialysis adequacy should be measured quarterly. This interval
seems too infrequent to me, because a patient could develop a
problem with the fistula and receive inadequate dialysis for as
long as 3 months before it is detected. As a practical suggestion,
for patients who are doing poorly from lack of appetite, chronic
diarrhea, dilated cardiomyopathy, persistent ascites, pleural
effusions, or any clinical disorder that could result from under-
dialysis, it is best to measure the adequacy of dialysis. This can
be done at any time simply by sending an extra pre-post-dialysis
BUN to the clinical laboratory. Only after adequate dialysis is
assured can the problem be appropriately addressed.
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DR. MADIAS: Can you elaborate on the effect of reuse on
dialyzer clearance?
DR. DEPNER: Yes, in this patient and recently in our dialysis
center as a whole, we have not seen a correlation between
dialyzer reuse and declining Kt/V, or between reuse and an
increase in apparent V. The ratio between modeled V and true
V or the ratio between modeled clearance and expected clear-
ance does not correlate with reuse. Protection from a reuse-
associated decline in clearance is provided by measurements of
fiber bundle volume with each use. When this volume falls
below 80% of its original value, the dialyzer is discarded. A 20%
reduction in volume corresponds to a 10% reduction in clear-
ance. Several years ago we found reductions in dialyzer clear-
ances that were ultimately traced to this part of the reuse
equipment. We were able to correct the problem and prevent
chronic underdialysis in our patients largely because we were
routinely modeling urea kinetics. In this case modeling served
two purposes: (1) it identified a problem that might have gone
undetected otherwise, and (2) it protected our patients from
underdialysis even before we had identified the source of the
problem. We knew their modeled Kt/V was inadequate, so we
increased their dialysis time. Delmez et al published a very
interesting experience in a series of 48 patients who had similar
declines in clearance related to reuse but apparently caused by
reuse-associated channeling of dialysate along one side of the
dialyzer [34]. We are constantly alert to the possibility of reuse
interfering with dialyzer clearance, but as currently practiced in
our center, we do not have problems with reuse.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): With frequent modeling, we find that we
need a way to organize our approach to the problems of
apparent abnormalities in estimated volume of distribution of
urea. You presented us with a comprehensive list of the factors
that could cause these abnormalities but not the frequency of
these causes. How often are these abnormalities due to prob-
lems with the dialyzer or the access? The case you presented
today is a troubling one because it suggests that measurements
of recirculation are not sufficient to detect intermittent recircu-
lation. When would you suggest that a patient with an abnor-
mally large apparent volume of distribution of urea undergo a
fistulogram irrespective of the measured recirculation?
DR. DEPNER: You raise a good question that I can only
partially answer. I can tell you that we measure recirculation in
virtually all our patients with unexplained discrepancies be-
tween V and expected V. In most there is no detectable
recirculation, and when the modeling is repeated we find that
the discrepancy has disappeared. We often never discover
exactly what caused the problem. I have focused attention on
these patients to see whether we aren't overlooking something.
Occasionally we see problems with blood pump or dialysate
pump calibration, and occasionally we see the "wall clock
syndrome." If you look at the records or talk to the technician,
in many cases the flow rates, dialyzer model, or time are
recorded incorrectly. Unfortunately in many cases no explana-
tion is available. Intermittent recirculation must be added to the
list of possibilities. This type of intermittent problem is not
easily studied because it is unpredictable and therefore requires
large numbers of patients and multiple independent measure-
ments of flow rates, recirculation, and clearances. No data are
available regarding the frequency of the various causes of
reduced dialyzer clearance and high V (Table 3). I suspect the
frequencies vary from center to center.
DR. MEYER: You commented that the V was a constant. Are
there times when a dialysis patient's volume changes from an
increase or decrease in lean body mass? Are there situations in
which we should look for a change in V?
DR. DEPNER: My purpose in emphasizing the constancy of
urea volume (V) was to contrast it with K and t, both of which
can change dramatically, K sometimes within a single dialysis
treatment. V is a true physiologic constant, measurable inde-
pendently of dialysis using, for example, D2O. It changes
slightly between dialyses as the patient gains weight, but that
change is easily measured. By convention, V is the patient's
urea distribution volume at "dry" weight, postdialysis. If the
patient gains or loses dry weight, V can change but the change
is signaled by the change in weight. Other identifiable changes
such as the accumulation of edema fluid or ascites would be
expected to influence V. When these changes are observed, V
can be remeasured, but the measurements are required infre-
quently, for example, at 3- or 4-month intervals. At present few
centers measure dialysis adequacy using dialysate methods.
When and if this becomes a more common practice, we will
have to pay more attention to V because the accuracy of V is
critical for this type of analysis. Bioimpedance measurements
have been used in Europe to measure both intracellular and
extracellular space, but the technique is not standardized and
its reproducibility varies. Using two-compartment BUN and
dialysate methods we have found that V is significantly lower in
hemodialyzed patients than predictions based on anthropomet-
ric formulae obtained from a normal population [18, 20]. The
reasons for lower V in our patients is not apparent but could
include subtle malnutrition, reductions in lean body mass, or
derangements of cellular volume-regulatory mechanisms. Oth-
ers have found extracellular volume to be normal or expanded
in hemodialyzed patients [15].
Da. HARRINGTON: What happened to your patient after the
stenoses were relieved? Second, is it time for another national
cooperative study on the adequacy of dialysis?
DR. DEPNER: The patient has fared well throughout all these
concerns about her V and her graft. As you can see from Table
1, her Kt/V fell to 0.8/dialysis at one point, but her target Kt/V
was also 0.8 at that time because she had a residual urea
clearance of 2.0 mI/mm. Retention of residual function 4 years
after starting hemodialysis in a patient with diabetic microvas-
cular disease is unusual but well documented in this patient
[82]. In addition to her native-kidney function, she was rela-
tively protected from underdialysis because she could not
tolerate high ultrafiltration rates. For this reason, dialysis was
prolonged beyond the time required to achieve her target Kt/V.
Following percutaneous dilation of her access stenoses, urea
modeling results normalized. The V and modeled Kt/V are now
45% and 47% of body weight and she continues to tolerate
dialysis well.
Do we need another national cooperative study? Yes, I think
we do. The question I would like to have answered by such a
study is, can we reduce morbidity and improve our patients'
sense of well-being and stamina by increasing K't/V above the
level that was established as a minimum by the previous
cooperative study? The new study might be more limited in
scope but would be designed to examine all the parameters of
Kd
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outcome that we can muster (not limited to morbidity and
mortality), using biocompatible dialyzers and bicarbonate dia-
lysate. The results of such a study would have far-reaching
consequences with respect to cost as well as clinical benefit.
DR. GEETHA NARAYAN (Division of Nephrology, St. Eliza-
beth's Hospital): In the case you presented, by demonstrating
that the dialyzer urea clearance matched the expected, manu-
facturer's standard urea clearance, you have effectively verified
that the membrane function and delivered blood flow rate are as
prescribed. If you can carefully verily that the delivered t was
also accurate, then the only possible error is V itself. But the V
measured through dialyzer clearance (by dialysate collection),
presumably more accurate, was not high and in the expected
range. That leaves you with recirculation as the only possible
explanation for the higher kinetic Vs. So why not go directly to
fistulogram and skip the recirculation test, especially given the
chances of false-negative results in your patient? For instance,
we know that the recirculation test can indeed be negative if the
arterial and venous needles are placed proximal and distal,
respectively, to a stenosed segment at any given dialysis
treatment.
DR. DEPNEIt: Our radiologists argue that we do not order
enough angiograms. Part of the motive for this recommendation
comes from their attempts to restore flow in clotted fistulas and
grafts. Percutaneous correction of the stenosis is much easier
before clotting occurs. Experience with cases like the patient
discussed today leads me to agree with them. This patient had
several findings on her physical examination alone that might
Appendix A. A more accurate formula for KtIV:
have justified earlier angiography. However, as a screening
test, angiography is too invasive and too expensive. Selection
of patients for angiography must lie somewhere between
screening all patients with high Vs from urea modeling and
restricting it to those with demonstrated recirculation. Clinical
judgment must play a role here and should include a thorough
physical examination of the access itself. My threshold for
ordering an angiogram of the access device is lower after
reviewing this case.
DR. MADIAS: Could you please comment on the merits of
using urea as opposed to any other solute in our dialysis
modeling?
DR. DEPNER: As a marker of dialyzer clearance and dialysis
effect in the patient, urea has several advantages. It is present in
high concentrations and is easily measured using standard
methods that have withstood the test of time. It is a stable,
small-molecular-weight compound that is uncharged but water
soluble and easily dialyzed. It distributes in total-body water
and diffuses relatively easily among body compartments. Urea
is also a marker for net protein catabolism, a factor that seems
to play a role in the genesis of uremic toxicity. Taken together,
these characteristics endow urea with advantages that far
outweigh those of any other compound as an indicator of
dialysis adequacy. Even if the putative uremic toxins are
identified, urea will probably remain a favored measure of the
dialyzer effect, because its removal is so dependent on dialyzer
function, and measurements of its generation give us informa-
tion about the patient's protein intake.
Appendix C. Dialysate method for measuring true V
amount removedThis formula for Kd•t/V incorporates volume changes during dialysis,
urea generation during dialysis, and native kidney function: v = (C-i)
change in concentration
—B1 G1C0(Kf+Bf+Krj)1
Kf=,(1 —Bf.t) G1— C(Kf+Bf+K,r)] (Bf+Krf) (A-i)
C0— Ce
(C-2)
(A-2) V is the volume of urea distribution (ml); A is the total dialysate urea N
content (mg); C,, is the predialysis BUN (mg/mi); C,, is the equilibrated
postdialysis BUN (mg/mi).Kf is KjV (fractional urea clearance); Gf is G/V (fractional urea
generation); B1 is —iV/(V.t) (fractional rate of volume change during Expand to include G and 1V (the effect of residual clearance is
dialysis); K is K,JV (fractional residual clearance). Because K1 occurs considered negligible):
on both sides of the equal sign, Equation A-I must be solved by
iteration using a programmable calculator or computer. v = A
— C,AV — G td (C-3)Co - Ce
Appendix B. Expected dialyzer clearance
Expected dialyzer clearance (Kd) can be calculated from the dialyzer
intrinsic clearance (K1) and flow rates when blood flow (Qb) is
countercurrent to dialysate flow (Qd) [2, 52]:
(B-i)
eZ — ii
Kd=Qb ez_I (B-2)
QaJ
Intrinsic clearance (K1) is the maximum clearance achievable for the
indicated solute at infinite blood and dialysate flow rates. It is a function
of the dialyzer's permeability and surface area and is often called the
dialyzer mass-transfer-area coefficient. Effective dialyzer clearance is
usually lower than the expected dialyzer clearance.
1V is the volume (weight) change during dialysis (ml); G is the urea
generation rate (mg/mm); t, is the dialysis duration (mm).
Appendix D. Methods for preventing access recirculation when
sampling blood
Low-flow method
1. Prepare syringes and needles for drawing blood
2. Stop ultrafiltration
3. Raise venous pressure alarm limit to its maximum
4. Reduce blood flow to 50 mI/mm
S. Clamp venous line between patient and drip chamber
6. Wait
until alarm sounds and pump stops
no longer than 30 seconds (stop pump manually)
7. Sample blood from arterial port Continued on next page
1534 Nephrology Forum: Urea modeling in dialysis
Appendix D. Continued
(Note: if the upper venous pressure limit cannot be set independently
of the lower limit, the stop-flow method may be used.)
Stop-flow method
1. Prepare syringes
2. Stop ultrafiltration
3. Stop blood pump and disconnect arterial (inflow) line
4. Withdraw 30 ml blood from the patient's arterial line with a
syringe
5. Withdraw sample for BUN within 30 seconds after stopping
blood pump
6. Replace the above 30 ml sample of blood
7. Reconnect arterial line
Reprint requests to Dr. T. A. Depner, Division of Nephrology, UCD
Professional Bldg, 4301 X Street, Sacramento, California 95817, USA
References
1. DEPNER TA: Hemodialysis urea modeling: the basics. Semin Dial
4:179—184, 1991
2. DEPNER TA: Prescribing Hemodialysis: A Guide to Urea Model-
ing, Boston, Kluwer, 1991
3. AEBIsCHER P, SCHORDERET D, JUILLERAT A, WAUTERS JP,
FELLAY G: Comparison of urea kinetics and direct dialysis quanti-
fication in hemodialysis patients. Trans Am Soc Art if Intern Organs
31:338—341, 1985
4. KJELLSTRAND C, ULAN R, ODAR-CEDERLOF I, ERICSSON F, SK-
RODER R, JACOBSSON S: All derived Kt/V overestimate and increas-
ingly deviate from true Kt/V as dialysis speed is increased and
dialysis time shortened. JAm Soc Nephrol 2:332, 1991
5. BARTH RH: Urea modeling and Kt/V: A critical appraisal. Kidney
liii 43 (suppl 41):S252—S260, 1993
6. GOTCH FA, SARGENT JA: A mechanistic analysis of the National
Cooperative Dialysis Study (NCDS). Kidney mt 28:526—534, 1985
7. SCHINDHELM K, FARRELL PC: Patient-hemodialyzer interactions.
Trans Am Soc Artif Intern Organs 24:357—365, 1978
8. THYLEN P, ERIcssoN F, ODAR-CEDERLOF I, KJELLSTRAND CM:
Hypertension profiling by total body water (TBW) determinations
in patients on chronic hemodialysis. mt jArtif Organs 14:18-22,
1991
9. ODAR-CEDERLOF I, ERICSSON F, ERIKSSON CG, KJELLSTRAND
CM: Oral antipyrin, a simple, accurate and non-bloody way of
measuring total body water in hemodialysis patients. J Am Soc
Nephrol 2:342, 1991
10. Kouw PM, OLTHOF CG, TER WEE PM, OE LP, DONKER AJ,
SCHNEIDER H, DE VRIES PM: Assessment of post-dialysis dry
weight: an application of the conductivity measurement method.
Kidney mt 41:440—444, 1992
11. MALCHESKY PS, ELLIS P, NOSSE C, MAGNUSSON M, LANKHORST
B, NAKAMOTO 5: Direct quantification of dialysis. Dial Transplant
11:42—44, 1982
12. GARRED U, DIGIUSEPPE B, CHAND W, MCCREADY W, CANAUD
B: KT/V and protein catabolic rate determination from serial urea
measurement in the dialysatc effluent stream. Artif Organs 16:248—
255, 1992
13. KESHAVIAH P, EBBEN J, LUHRING D, EMERSON P, COLLINS A:
Clinical evaluation of a new on-line monitor of dialysis adequacy. .J
Am Soc Nephrol 3:374, 1992
14. DEPNER TA: Approach to hemodialysis urea modeling, in The
Principles and Practice of Dialysis, edited by Henrich WL, Wil-
liams & Wilkins, in press
15. COLES GA: Body composition in chronic renal failure. Q J Med
41:25—47, 1972
16. BALJER JH, BRooKs CS: Body fluid composition in chronic renal
failure. C/in Nephrol 16:114—118, 1981
17. ILSTRUP K, HANSON 0, SHAPIRO W, KESHAVIAH P: Examining the
foundations of urea kinetics. Trans Am Soc Artif Intern Organs
31:164—168, 1985
18. DEPNER TA, WAGNER JM, CHEER AY: Low urea distribution
volumes in stable hemodialyzed patients. JAm Soc Nephrol 3:362,
1992
19. HUME R, WEYERS E: Relationship between total body water and
surface area in normal and obese subjects. J C/in Pathol 24:234—
238, 1971
20. WATSON PE, WATSON ID, BATT RD: Total body water volumes for
adult males and females estimated from simple anthropometric
measurements. Am J Clin Nutr 33:27—39, 1980
21. SAHA LK, VAN STONE JC: Differences between KT/V measured
during dialysis and KT/V predicted from manufacturer clearance
data. mt j ArtifOrgans 15:465—469, 1992
22. COLTON CK, LOWRIE EG: Hemodialysis: physical principles and
technical considerations, in The Kidney, edited by BRENNER BM,
RECTOR FC Ja, Philadelphia, Saunders, 1981, pp 2425—2489
23. LIM VS, FLANIGAN MJ, FANOMAN J: Effect of hematocrit on
solute removal during high efficiency hemodialysis. Kidney mt
37:1557—1562, 1990
24. DAUGIRDAS JT, DEPNER TA: A nomogram approach to hemodial-
ysis urea modeling. Am J Kidney Dis 23:33—40, 1994
25. SCHMIDT DF, SCHNIEPP BJ, KURTZ SB, MCCARTHY JT: Inaccu-
rate blood flow rate during rapid hemodialysis. Am J Kidney Dis
17:34—37, 1991
26. DEPNER TA, RIZWAN 5, STASI TA: Pressure effects on roller pump
blood flow during hemodialysis. ASAIO Trans 36:M456—M459,
1990
27. FARRELL PC, WARD RA, SCHINDHELM K, GOTCH FA: Precise
anticoagulation for routine hemodialysis. J Lab C/in Med 92:164—
176, 1978
28. SARGENT JA, GOTCH FA: Mathematic modeling of dialysis ther-
apy. Kidney mt 18 (suppl 10):S2—S10, 1980
29. SCHMIDT R, ZASUWA 0, SCHELL D, DUMLER F: Proper dialyzer
reprocessing does not impair urea mass transfer. JAm Soc Nephrol
2:349, 1991
30. FARRELL PC, ESCHBACH JW, VIZZO JE, BABB AL: Hemodialyzer
reuse: estimation of area loss from clearance data. Kidney In!
5:446—450, 1974
31. DEPHER TA: Pitfalls in quantitating hemodialysis. Semin Dial
6: 127—133, 1993
32. GOTCH F: Mass transport in reused dialyzers. Proc C/in Dial
Transpl Forum 10:81—85, 1980
33. LOWRIE EG, LAIRD NM, PARKER TF, SARGENT JA: Effect of the
hemodialysis prescription on patient morbidity: Report from the
National Cooperative Dialysis Study. N Engl J Med 305:1176-1181,
1981
34. DELMEZ JA, WEERTS CA, HASAMEAR PD, WINDUS DW: Severe
dialyzer dysfunction undetectable by standard reprocessing valida-
tion tests. Kidney In! 36:478—484, 1989
35. GOTCH FA: Kinetic modeling in hemodialysis, in Clinical Dialysis
(2nd ed), edited by NISsEN5ON AR, GENTILE DE, FINE RN,
Norwalk, CT, Appleton and Lange, 1990, pp 118—146
36. COLLINS DM, LAMBERT MB, MIDDLETON JP, PROCTOR RK,
DAVIDSON CJ, NEWMAN GE, SCHWAB SJ: Fistula dysfunction:
Effect on rapid hemodialysis. Kidney In! 41:1292—1296, 1992
37. LEVY SS, SHERMAN RA, NOSHER JL: Value of clinical screening
for detection of asymptomatic hemodialysis vascular access steno-
ses. Angiology 43:421—424, 1992
38. WINDUS DW, AUDRAIN J, VANDERSON R, JENDRISAK MD, PICU5
D, DELMEZ JA: Optimization of high-efficiency hemodialysis by
detection and correction of fistula dysfunction. Kidney Int 38:337—
341, 1990
39. FAN PY, SCHWAB SJ: Vascular access: concepts for the 1990s
(editorial). JAm Soc Nephrol 3:1—11, 1992
40. SHERMAN RA, LEVY SS: Rate-related recirculation: the effect of
altering blood flow on dialyzer recirculation. Am J Kidney Dis
17:170—173, 1991
41. DEPNER T, RIZWAN 5, CHEER A, WAGNER J: Peripheral urea
disequilibrium during hemodialysis is temperature-dependent. J
Am Soc Nephrol 2:321, 1991
42. DEPNER TA, RIZWAN S. CHEER AY, WAGNER J, EDER LA: High
venous urea concentrations in the opposite arm: a consequence of
hemodialysis-induced compartment disequilibrium. JAm Soc Artif
Intern Organs 37:141—143, 1991
Nephrology Forum: Urea modeling in dialysis 1535
43. VAN STONE J, JONES M: Peripheral venous blood is not the
appropriate specimen to determine recirculation rate. J Am Soc
Nephrol 2:354, 1991
44. TATTERSALL JE, FARRINGTON K, RANIGA PD, THOMPSON H,
T0MLIN50N C, ALDRIDGE C, GREENWOOD RN: Haemodialysis
recirculation detected by the three-sample method is an artefact.
Nephroi Dial Transplant 8:60—63, 1993
45. HESTER RL, CURRY E, BOWER J: The determination of hemodial-
ysis blood recirculation using blood urea nitrogen measurements.
Am J Kidney Dis 20:598—602, 1992
46. GREENWOOD RN, ALDRIDGE C, GOLDSTEIN L: Assessment of
arteriovenous fistulae from pressure and thermal dilution studies:
clinical experience in forearm fistulae. Clin Nephrol 23:189—197,
1985
47. SCHWAB SJ, RAYMOND JR, SAEED M, NEWMAN GE, DENNIS PA,
BOLLINGER RR: Prevention of hemodialysis fistula thrombosis.
Early detection of venous stenoses. Kidney mt 36:707—711, 1989
48. BESARAB A, MORITZ M, SULLIVAN K, DORRELL S, PRICE JJ:
Venous access pressures and the detection of intra-access stenosis.
ASAIO J 38:M519—M523, 1992
49. DEPNER TA: Diagnostic value of vascular access compression.
Semin Dial 6:271—272, 1993
50. DEPNER TA: Refining the model of urea kinetics: compartment
effects. Semin Dial 5:147—154, 1992
51. SCHNEDITZ D, KAUFMAN AM, POLASCHEGG HD, LEVIN NW,
DAUGIRDAS JT: Cardiopulmonary recirculation during hemodialy-
sis, Kidney mt 42: 1450—1456, 1992
52. SARGENT JA, GOTCH FA: Principles and biophysics of dialysis, in
Replacement of Renal Function by Dialysis (3rd ed), edited by
MAHER JF, Dordrecht, Kluwer, 1989, pp 87—143
53. FROST TH, KE1u DNS: Kinetics of hemodialysis: A theoretical
study of the removal of solutes in chronic renal failure compared to
normal health. Kidney mt 12:41—50, 1977
54. GUTHKE R, GUNTHER K, STEIN G, KNORRE WA: Two-pool model
analysis of data in hemodialysis by means of programmable pocket
calculator TI 59. Comput Methods Programs Biomed 19:189-195,
1985
55. RENKIN EM: Effects of blood flow on diffusion kinetics in isolated
perfused hindlegs of cats: a double circulation hypothesis. Am J
Physiol 183:125—136, 1955
56. RENKIN EM: The relation between dialysance, membrane area,
permeability and blood flow in the artificial kidney. Trans Am Soc
Artif Intern Organs 2:102—105, 1956
57. GIBALDI M, PERRIER D: Pharmacokinetics, New York, Marcel
Dekker, mc, 1982
58. SCHNEDITZ D, VAN STONE JC, DAUGIRDAS JT: A regional blood
circulation alternative to in-series two-compartment urea kinetic
modeling. ASAIO J 39:1993
59. SCHNEDITZ D, DAUGIRDAS JT, Cu GA, MoRRIs AT, POLASCHEGG
HD, LhVIN NW, KAUFMAN AM: Impact of cardiopulmonary
recirculation on measurement of access recirculation. J Am Soc
Nephrol3:393, 1992
60. GARRED U, RITTAU M, MCCREADY W, CANAUD B: Urea kinetic
modelling by partial dialysate collection. mt J Artif Organs 12:96—
102, 1989
61. DEPNER TA, SINGH J: Dialysate urea modeling: a more precise
method (abstract). Abstr mt Soc Nephrol 11:232, 1990
62. LAIRD NM, BERKEY CS, LOWRIE EG: Modeling success or failure
of dialysis therapy: the National Cooperative Dialysis Study.
Kidney Im' 23 (suppl l3):SlOl—S 106, 1983
63. SARGENT JA: Shortfalls in the delivery of dialysis. Am J Kidney Dir
15:500—510, 1990
64. GOTCH FA, YARIAN 5, KEEN M: A kinetic survey of US hemodi-
alysis prescriptions. Am J Kidney Dis 15:511—515, 1990
65. LEFEBVRE JM, SPANNER E, HEIDENHEIM AP, LINDSAY RM:
Kt/V: Patients do not get what the physician prescribes. ASAIO
Trans 37:M132—M133, 1991
66. DELMEZ JA, WINDU5 DW, THE ST. LOUIS NEPHROLOGY STUDY
GROUP: Hemodialysis prescription and delivery in a metropolitan
community. Kidney mt 41:1023—1028, 1992
67. HAKIM RM, DEPNER TA, PARKER TF: In-depth review: Adequacy
of hemodialysis. Am J Kidney Dis 20:107—123, 1992
68. DAUGIRDAS JT: Dialysis hypotension: A hemodynamic analysis
(editorial). Kidney mt 39:233—246, 1991
69. OLTHOF CG, DE VRIES PM, KOUW PM, OE PL, GERLAG P0,
SCHNEIDER H, DONKER AJ: The recovery of the fluid balance after
hemodialysis and hemofiltration. Clin Nephrol 37:135—139, 1992
70. RoNco C, BRENDOLAN A, CREPAIDI C, LA GRECA G: Ultrafiltra-
tions-rate und dialyse-hypotension. Dialyse J 40:8—15, 1992
71. PEDRINI LA, ZEREIK S, RASMY 5: Causes, kinetics and clinical
implications of post-hemodialysis urea rebound. Kidney mt 34:8 17—
824, 1988
72. TESCHAN PE, GINN HE, BOURNE JR. WARD JW: Neurobehavioral
probes for adequacy of dialysis. Trans Am Soc Art if Intern Organs
23:556—560, 1977
73. TESCHAN PE, GINN HE, BOURNE JR, WARD JW, HAMEL B,
NUNNALLY JC, Musso M, VAUGHN WK: Quantitative indices of
clinical uremia. Kidney ml 15:676—697, 1979
74. BERGSTROM J, FURST P: Uraemic toxins, in Replacement of Renal
Function by Dialysis (2nd ed), edited by DRUKKER W, PARSONS
FM, MAHER iF, Boston, Martinus Nijhoff, 1983, pp 354—390
75. VANHOLDER R, SCHOOTS A, RINGOIR 5: Uremic toxicity, in
Replacement of Renal Function by Dialysis (3rd ed), edited by
MAHER JF, Dordrecht, Kluwer Academic Publishers, 1989, pp 4—19
76. COLLINS AJ, HANSON G, UMEN A, KJELLSTRAND C, KESHAVIAH
P: Changing risk factor demographics in end-stage renal disease
patients entering hemodialysis and the impact on long-term mortal-
ity. Am J Kidney Dis 15:422—432, 1990
77. GOTCH FA, UEHLINGER DE: Mortality rate in US dialysis patients.
Dial Transplant 20:255—257, 1991
78. ACCHIARDO SR, HATFEN KW, RUVINSKY Mi, DYSON B, FULLER
J, MOORE LW: Inadequate dialysis increases gross mortality rate.
ASAIO J 38:M282—M285, 1992
79. COLLINS A, LIA0 M, UMEN A, HANSON G, KESHAVIAH P: Diabetic
hemodialysis patients treated with a high KT/V have a lower risk of
death than standard KT/V (abstract). J Am Soc Nephrol 2:318,
1991
80. LOWRIE EG, LEW NL: Death risk in hemodialysis patients: The
predictive value of commonly measured variables and an evalua-
tion of death rate differences between facilities. Am J Kidney Dir
15:458—482, 1990
81. DEPNER TA: Estimation of Kt/V from URR for varying levels of
weight loss: a bedside graphic aid. Semin Dial 6:242, 1993
82. LYSAGHT Mi, VONESH E, GOTCH F, IBELS L, KEEN M, LINDHOLM
B, NOLPH DK, POLLOCK CA, PROWANT B, FARRELL PC: The
influence of dialysis treatment modality on the decline of remaining
renal function. J Am Soc Artif Intern Organs 37:598—604, 1991
83. SARGENT JA, GOTCH FA: Principles and biophysics of dialysis, in
Replacement of Renal Function by Dialysis (2nd ed), edited by
DRUKKER W, PARSONS FM, MAHER JF, Boston, Martinus Nijhoff,
1983, pp 53—96
84. SHERMAN RA, LEVY SS: Assessment of a two-needle technique for
the measurement of recirculation during hemodialysis. Am J Kid-
ney Dis 18:80—83, 1991
85. KAUFMAN AM, KRAEMER M, GODMERE RO, Moiuus AT, AMER-
UNG R, POLASCHEGG HD, LEVIN NW: Hemodialysis access recir-
culation measurement by blood temperature monitoring—a new
technique. JAm Soc Nephrol 2:332, 1991
86. HESTER RU, ASHCRAFT D, CURRY E, BOWER J: Non-invasive
determination of recirculation in the patient on dialysis. ASAIO J
38:M190—Ml93, 1992
